Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

[1]  J. A. Scarlett,et al.  Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. , 2001, The Journal of clinical endocrinology and metabolism.

[2]  J. A. Scarlett,et al.  Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. , 2000, The Journal of clinical endocrinology and metabolism.

[3]  S. Wardlaw,et al.  Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. , 2000, The Journal of clinical endocrinology and metabolism.

[4]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[5]  R. Utiger.  Treatment of acromegaly. , 2000, The New England journal of medicine.

[6]  M. Culler,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify , 2022 .

[7]  P. Kelly,et al.  The Human Growth Hormone Antagonist B2036 Does Not Interact with the Prolactin Receptor. , 1999, Endocrinology.

[8]  J. A. Scarlett,et al.  Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. , 1999, Diabetes.

[9]  P. Black,et al.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[10]  S. Wardlaw,et al.  Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. , 1998, Journal of neurosurgery.

[11]  A. Beckers,et al.  Cabergoline in the treatment of acromegaly: a study in 64 patients. , 1998, The Journal of clinical endocrinology and metabolism.

[12]  A. J. Lely,et al.  The Role of Radiotherapy in Acromegaly , 1997 .

[13]  H. Sandler,et al.  Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. , 1997, The Journal of clinical endocrinology and metabolism.

[14]  L. Velloso,et al.  Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues , 1997, Molecular and Cellular Endocrinology.

[15]  J. Kopchick,et al.  A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. , 1996, Endocrinology.

[16]  G. Striker,et al.  Inhibition of diabetic nephropathy by a GH antagonist: a molecular analysis. , 1996, Kidney international.

[17]  W. Young,et al.  Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.

[18]  G. Striker,et al.  Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. , 1995, Endocrinology.

[19]  P. Sönksen,et al.  Growth Hormone and Diabetes mellitus , 1993 .

[20]  A. Barkan,et al.  Treatment of acromegaly with dopamine agonists. , 1992, Endocrinology and metabolism clinics of North America.

[21]  F Pedersen,et al.  Volume of Pituitary Macroadenomas: Assessment by MRI , 1992, Journal of computer assisted tomography.

[22]  D. Goeddel,et al.  Rational design of potent antagonists to the human growth hormone receptor. , 1992, Science.

[23]  A. Harris,et al.  Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. , 1991, Archives of internal medicine.

[24]  J. Reubi,et al.  The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. , 1989, The Journal of clinical endocrinology and metabolism.

[25]  B. Beaufrère,et al.  Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. , 1986, The American journal of physiology.